Favik is an online platform that sets business for influencers. Founded in 2020, the company is headquartered in Bogotá, Colombia.
SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company (MLSoC) that develops machine learning technology to deliver a software-centric platform. With push-button performance, they enable effortless ML deployment and scaling at the embedded edge by allowing customers to address any computer vision problem while achieving 10x better performance at the lowest power. The company's hardware-to-software stack flexibly adjusts to any framework, network, model, sensor, or modality all in one platform. Edge ML applications that run completely on the SiMa.ai MLSoC see an increase in performance and energy efficiency and bring higher fidelity intelligence to ML use cases spanning computer vision to generative AI.
Cytoki Pharma is a biotechnology company that specializes in developing novel medicines for diseases with a significant unmet medical need with a focus on serious diseases caused by epithelial injury. CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury having an unmet medical need. Cytoki’s lead program is an engineered long-acting IL-22 protein licensed from a major pharmaceutical company.A correctly functioning immune system is essential for keeping us healthy in the multitude of challenges our organism encounters. Numerous medicines are based on principles that activate or deactivate key proteins in the immune system in a disease context. IL-22 is a key cytokine (a class of proteins released from immune cells) in securing the survival and repair after an injury. It is the immune system’s “Survive and Recover” signal to the tissue. Our lead program is harnessing the power of IL-22, in treatment of organ injuries, through a modified IL-22 protein engineered to have optimal pharmaceutical properties.
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
H55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous through the use of electric propulsion systems and sensor technology.
Natron Energy is an energy storage company that develops sodium ion battery solutions leveraging Prussian Blue electrode materials. Natron’s battery products are based on a unique Prussian Blue chemistry and can integrate into a wide variety of energy storage applications, ranging from critical backup power systems to EV fast charging and behind-the-meter applications.
Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. Orca Bio has developed a pipeline of proprietary technologies that have the potential to impact over 100 malignant and auto-immune diseases. Orca has assembled a team of world-leading experts and technologists to execute this vision.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company (MLSoC) that develops machine learning technology to deliver a software-centric platform. With push-button performance, they enable effortless ML deployment and scaling at the embedded edge by allowing customers to address any computer vision problem while achieving 10x better performance at the lowest power. The company's hardware-to-software stack flexibly adjusts to any framework, network, model, sensor, or modality all in one platform. Edge ML applications that run completely on the SiMa.ai MLSoC see an increase in performance and energy efficiency and bring higher fidelity intelligence to ML use cases spanning computer vision to generative AI.
Arctos Medical is a spin-off company from the University of Bern and has developed a revolutionary gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Serotiny is an AI-based platform that invents multi-domain therapeutic proteins for CAR T-cell therapies. It also helps in developing multi-domain proteins for cell therapies for the treatment of cancer and a genetic disorder.
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.
H55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous through the use of electric propulsion systems and sensor technology.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases. This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health. The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage.
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
Private Equity Round in 2014
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light and unobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light and unobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light and unobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences.
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
SBA Materials is dedicated to the development of functional porous inorganic and inorganic/organic hybrid materials for a wide range of technologies. Different synthesis and processing conditions allow for a variety of material compositions, structures, and applications. They can be fabricated as thin and thick films, powders, fibers, and even optically clear solid monoliths all consisting of highly ordered mesoporous networks. The resulting surface area is extraordinarily high and can be chemically functionalized, e.g. with organic dyes, quantum dots, magnetic materials, or biomaterials enabling applications ranging from electronics and optics to sensors, catalysts. SBA Materials is located in Albuquerque, NM, at the Science and Technology Park, adjacent to the University of New Mexico and the Sandia National Laboratories Materials Research Center. The facility includes R&D laboratories, offices, and meeting space.
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
Xtellus, Inc. provides reconfigurable optical add/drop multiplexers (ROADM) technology and dynamic optical modules for agile optical networking systems. It offers wavelength selective switches, wavelength blockers, edge wavelength selective switches, and ROADM modules with integrated power monitoring and muxes/demuxes; and liquid crystal optical processors. Xtellus, Inc. was founded in 2000 and is based in Morris Plains, New Jersey. It has manufacturing and development facilities in Israel and South Korea. The company also has a research and development facility in Jerusalem, Israel. As of December 17, 2009, Xtellus, Inc. operates as a subsidiary of Oclaro, Inc.
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.